Welcome to our dedicated page for Exelixis SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Exelixis, Inc. (EXEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed oncology-focused biopharmaceutical company, Exelixis uses these filings to report material events, financial results, capital allocation decisions and changes in senior leadership.
Form 8-K filings for EXEL include items such as quarterly financial results and corporate updates, stock repurchase program authorizations and executive appointments or departures. For example, Exelixis has filed 8-Ks describing the authorization of a stock repurchase program for up to a specified amount of common stock before a stated date, as well as the appointment of an Executive Vice President, Research and Development and the planned transition of its General Counsel role. These filings complement the company’s earnings press releases by providing structured information on results of operations and significant corporate actions.
Investors and analysts can use Exelixis’ SEC filings to track how the company reports revenue from its cabozantinib franchise, outlines research and development and selling, general and administrative expenses, and communicates guidance ranges for future periods. While detailed financial statements and management discussion are found in periodic reports such as Forms 10-K and 10-Q, current reports on Form 8-K highlight timely developments that may affect the company’s outlook or governance.
On Stock Titan, EXEL filings are accompanied by AI-powered summaries designed to clarify the key points in complex documents. These summaries help readers quickly understand the implications of new filings, from capital return plans to leadership changes, while links to the full text allow for deeper review. The filings page also serves as a starting point for researching topics such as repurchase authorizations, executive transitions and other events that Exelixis has deemed material enough to disclose under SEC rules.
Exelixis, Inc. is an oncology-focused biopharma built around its cabozantinib franchise, marketed as CABOMETYX and COMETRIQ for multiple cancers including renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, neuroendocrine tumors and medullary thyroid cancer.
In 2025, Exelixis recorded $2.12 billion in net product revenue from CABOMETYX and COMETRIQ, up about 17% year over year, and earned $179.2 million in cabozantinib royalties from partners Ipsen and Takeda, marking its ninth consecutive profitable year. Collaboration deals generate additional milestones and royalties.
The company remains heavily reliant on CABOMETYX but is building a broad pipeline. Lead candidate zanzalintinib, a next-generation VEGF-receptor TKI, is in multiple late-stage trials across colorectal, renal cell, neuroendocrine tumors and meningioma, with a U.S. NDA accepted for previously treated metastatic colorectal cancer and a PDUFA target date of December 3, 2026.
Additional early-stage programs include small molecule USP1 inhibitor XL309 and several biotherapeutics, such as ADC XB010, bispecific antibody XB628 and TF-targeting ADC XB371. Extensive collaborations with Ipsen, Takeda, Roche, Bristol Myers Squibb, Merck and others support global commercialization of cabozantinib and co-fund development of new regimens.
Exelixis reported stronger results for 2025, with total revenues of $2.32 billion versus $2.17 billion in 2024, driven mainly by its cabozantinib cancer franchise. U.S. cabozantinib net product revenues reached $2.12 billion, and global franchise revenues with partners totaled $2.9 billion.
GAAP net income rose to $782.6 million, or $2.78 diluted EPS, up from $1.76 a year earlier; non-GAAP diluted EPS was $3.08. Fourth quarter diluted EPS was $0.88 GAAP and $0.94 non-GAAP. The company repurchased $264.5 million of stock in Q4 and has retired 76.7 million shares cumulatively.
For 2026, Exelixis guides total revenues to $2.525–$2.625 billion and net product revenues to $2.325–$2.425 billion. The FDA has accepted its NDA for zanzalintinib in previously treated metastatic colorectal cancer, with a PDUFA target date of December 3, 2026, and multiple pivotal zanzalintinib trials are advancing.
Exelixis, Inc. President and CEO Michael Morrissey reported equity compensation activity involving company common stock. On January 15, 2026, he acquired 548,073 shares of common stock at $0 per share through the vesting of a performance-based restricted stock unit award. On the same date, 139,524 shares were withheld at $45.23 per share to cover taxes related to this vesting.
After these transactions, Morrissey held 1,825,241 shares of Exelixis common stock directly. In addition, 1,714,404 shares were held indirectly by the Morrissey Family Living Trust, and 17,728 shares were held indirectly through the Exelixis 401(k) Plan. A separate grant includes 1,690,729 shares that may be issued in the future upon vesting of restricted stock units and performance-based units previously awarded.
Exelixis, Inc. executive Aftab Dana, EVP of Research and Development, reported equity award activity tied to a performance-based restricted stock unit (PSU) grant. On January 15, 2026, 119,578 shares of common stock were acquired at $0 per share upon certification that certain PSU performance criteria were achieved. On the same date, 27,254 shares were withheld at $45.23 per share to cover taxes from this vesting. After these transactions, Dana beneficially owned 733,102 shares of Exelixis common stock directly, which includes 491,096 shares that will be issued upon future vesting of restricted stock units and PSUs granted on March 31, 2025, and also held 5,835 shares indirectly through the Exelixis 401(k) Plan as of January 14, 2026.
Exelixis, Inc. EVP, Commercial Haley J. Patrick reported equity award activity tied to performance-based restricted stock units. On January 15, 2026, 139,508 shares of common stock were acquired at $0 per share upon vesting of a performance-based restricted stock unit award originally granted on April 3, 2023, following the Compensation Committee’s certification that certain performance criteria had been achieved.
On the same date, 32,332 shares were withheld at a price of $45.23 per share to cover taxes related to this PSU vesting. After these transactions, Patrick directly beneficially owned 481,205 shares of Exelixis common stock, which includes 443,784 shares that will be issued upon future vesting of previously granted RSUs and one-time performance stock units awarded on March 31, 2025.
Exelixis, Inc. EVP and CFO Christopher J. Senner reported equity award activity on January 15, 2026. He acquired 149,474 shares of common stock at $0 per share upon vesting of performance-based restricted stock units granted on April 3, 2023, after the compensation committee certified achievement of required performance criteria.
To cover taxes related to this vesting, 40,459 shares were withheld by Exelixis at a price of $45.23 per share. After these transactions, Senner directly beneficially owns 1,076,857 shares of Exelixis common stock, which include 494,177 shares that will be issued upon future vesting of previously granted RSUs and PSUs. He also indirectly holds 2,723 shares through the Exelixis 401(k) plan as of January 14, 2026.
Exelixis, Inc. filed a current report to disclose that on January 11, 2026 it issued a press release with preliminary, unaudited financial results for the fiscal year ended January 2, 2026. The release also provided financial guidance for the fiscal year ending January 1, 2027 and included an update on the company’s business.
The company notes that the audit of its fiscal 2025 financial statements is ongoing and could lead to changes in the information contained in the press release. Exelixis states it plans to report its audited financial results for the fiscal year ended January 2, 2026 on February 10, 2026. The press release is furnished as Exhibit 99.1 and is not deemed filed for liability purposes.
Exelixis, Inc. (EXEL) director David Johnson, together with Caligan Partners LP, reported an open-market purchase of 27,532 shares of common stock on 11/25/2025 at a price of $43.122 per share. After this transaction, 1,553,262 shares are reported as indirectly owned through Caligan-managed funds and accounts, while 18,176 shares are reported separately, which include 9,088 shares that will be issued upon vesting of restricted stock units to Johnson. The reporting persons state they disclaim beneficial ownership of the securities beyond any pecuniary interest and note that Caligan may be deemed a director by deputization because Johnson serves on the Exelixis board.
Exelixis, Inc. executive reports insider stock sales. The company’s EVP, Commercial, filed a Form 4 showing sales of a total of 72,230 shares of Exelixis common stock on November 20–21, 2025.
On November 20, 2025, the executive sold 10,000 shares at a weighted average price of $42.11, while a spouse’s account sold 23,539 shares at a weighted average price of $41.93, and a 401(k) account sold 10,648 shares at a weighted average price of $41.77. On November 21, 2025, the executive sold 28,043 shares at a weighted average price of $42.58.
Following these transactions, the executive beneficially owns 374,029 shares, consisting of Exelixis common stock that will be issued upon vesting of restricted stock units and performance-based restricted stock units, each representing the right to receive one share of common stock.
Exelixis, Inc. (EXEL) reported an insider stock gift by a senior executive. The company’s EVP of Research and Development filed a Form 4 disclosing that on November 21, 2025, they gifted 24,000 shares of Exelixis common stock to a donor-advised fund at a reported price of $0, reflecting a charitable transfer rather than a market sale.
After this gift, the executive beneficially owned 640,778 shares directly, which includes 431,306 shares of common stock scheduled to be issued upon vesting of restricted stock units and performance-based restricted stock units. The filing also shows 5,835 shares held indirectly through the Exelixis, Inc. 401(k) Plan based on a plan statement dated November 20, 2025.